Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Comparing ranibizumab and aflibercept in a treat and extend algorithm evaluating the number
of needed injections over a 18 month period in patients with newly diagnosed CRVO.